UF startup Myosin Therapeutics has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund (FCIF) to support the company’s STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients newly diagnosed with glioblastoma (GBM).
FCIF is a statewide initiative designed to accelerate the development of innovative cancer therapies and strengthen Florida’s life sciences ecosystem by supporting promising research programs and emerging biotechnology companies. Myosin Therapeutics was selected for funding based on the scientific innovation and clinical potential of MT-125, the company’s lead oncology therapeutic candidate. The award will specifically support clinical trial activities being conducted at the Mayo Clinic campus in Jacksonville, FL.
Read more about Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial.
